274 related articles for article (PubMed ID: 29063609)
21. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
[TBL] [Abstract][Full Text] [Related]
22. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
[TBL] [Abstract][Full Text] [Related]
23. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
24. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
25. Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization.
Raish M; Khurshid M; Ansari MA; Chaturvedi PK; Bae SM; Kim JH; Park EK; Park DC; Ahn WS
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1173-86. PubMed ID: 22419440
[TBL] [Abstract][Full Text] [Related]
26. Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study.
Bekos C; Grimm C; Brodowicz T; Petru E; Hefler L; Reimer D; Koch H; Reinthaller A; Polterauer S; Polterauer M
Sci Rep; 2017 Nov; 7(1):14474. PubMed ID: 29101329
[TBL] [Abstract][Full Text] [Related]
27. FGFR4 promotes nuclear localization of GABP to inhibit cell apoptosis in uterine leiomyosarcoma.
Zhang P; Zhang H; Wang Y
Cell Tissue Res; 2021 Feb; 383(2):865-879. PubMed ID: 33151453
[TBL] [Abstract][Full Text] [Related]
28. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens T; Annibali D; Coosemans A; Trovik J; Ter Haar N; Colas E; Garcia-Jimenez A; Van de Vijver K; Kruitwagen RP; Brinkhuis M; Zikan M; Dundr P; Huvila J; Carpén O; Haybaeck J; Moinfar F; Salvesen HB; Stukan M; Mestdagh C; Zweemer RP; Massuger LF; Mallmann MR; Wardelmann E; Mints M; Verbist G; Thomas D; Gommé E; Hermans E; Moerman P; Bosse T; Amant F
Clin Cancer Res; 2017 Mar; 23(5):1274-1285. PubMed ID: 28232476
[No Abstract] [Full Text] [Related]
29. Oncomirs Expression Profiling in Uterine Leiomyosarcoma Cells.
de Almeida BC; Garcia N; Maffazioli G; dos Anjos LG; Baracat EC; Carvalho KC
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295562
[TBL] [Abstract][Full Text] [Related]
30. May Sonic Hedgehog proteins be markers for malignancy in uterine smooth muscle tumors?
Garcia N; Bozzini N; Baiocchi G; da Cunha IW; Maciel GA; Soares Junior JM; Soares FA; Baracat EC; Carvalho KC
Hum Pathol; 2016 Apr; 50():43-50. PubMed ID: 26997437
[TBL] [Abstract][Full Text] [Related]
31. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.
Brewer Savannah KJ; Demicco EG; Lusby K; Ghadimi MP; Belousov R; Young E; Zhang Y; Huang KL; Lazar AJ; Hunt KK; Pollock RE; Creighton CJ; Anderson ML; Lev D
Clin Cancer Res; 2012 Sep; 18(17):4633-45. PubMed ID: 22821997
[TBL] [Abstract][Full Text] [Related]
32. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.
Dhingra S; Rodriguez ME; Shen Q; Duan X; Stanton ML; Chen L; Zhang R; Brown RE
Int J Clin Exp Pathol; 2010 Jan; 4(2):134-46. PubMed ID: 21326806
[TBL] [Abstract][Full Text] [Related]
33. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
[TBL] [Abstract][Full Text] [Related]
34. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
[TBL] [Abstract][Full Text] [Related]
35. Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.
Lee PJ; Yoo NS; Hagemann IS; Pfeifer JD; Cottrell CE; Abel HJ; Duncavage EJ
Exp Mol Pathol; 2017 Feb; 102(1):156-161. PubMed ID: 28093192
[TBL] [Abstract][Full Text] [Related]
36. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
Shan W; Akinfenwa PY; Savannah KB; Kolomeyevskaya N; Laucirica R; Thomas DG; Odunsi K; Creighton CJ; Lev DC; Anderson ML
Clin Cancer Res; 2012 Jun; 18(12):3352-65. PubMed ID: 22535157
[TBL] [Abstract][Full Text] [Related]
37. Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile.
Astolfi A; Nannini M; Indio V; Schipani A; Rizzo A; Perrone AM; De Iaco P; Pirini MG; De Leo A; Urbini M; Secchiero P; Pantaleo MA
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751892
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor II messenger RNA-binding protein-3 is an independent prognostic factor in uterine leiomyosarcoma.
Yasutake N; Ohishi Y; Taguchi K; Hiraki Y; Oya M; Oshiro Y; Mine M; Iwasaki T; Yamamoto H; Kohashi K; Sonoda K; Kato K; Oda Y
Histopathology; 2018 Apr; 72(5):739-748. PubMed ID: 29077232
[TBL] [Abstract][Full Text] [Related]
39. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
[TBL] [Abstract][Full Text] [Related]
40. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy.
Danielson LS; Menendez S; Attolini CS; Guijarro MV; Bisogna M; Wei J; Socci ND; Levine DA; Michor F; Hernando E
Am J Pathol; 2010 Aug; 177(2):908-17. PubMed ID: 20558575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
